Literature DB >> 32395477

MicroRNA-18a induces epithelial-mesenchymal transition like cancer stem cell phenotype via regulating RKIP pathway in pancreatic cancer.

Honggang Kang1, Dan Ma1, Jing Zhang1, Jun Zhao1, Mengxiang Yang1.   

Abstract

BACKGROUND: Pancreatic cancer is a devastating invasive disease. Understanding the molecular mechanism of metastasis of this cancer is basis for its treatment and prevention.
METHODS: Pancreatic cancer tissues and normal adjacent tissues were collected from patients tour hospital. Western blotting and a sphere growth and invasion assay were performed to conduct analysis. Pancreatic ductal adenocarcinoma cell Line PANC-1 were cultured. To test the level of Raf-1 kinase inhibitor protein (RKIP), immunofluorescence analyses were performed.
RESULTS: In this study, we showed that expression of RKIP was downregulated in pancreatic cancer. RKIP can inhibit epithelial to mesenchymal transition (EMT) in PANC-1 cells. MicroRNA-181a (miR-181a) has a high expression in pancreatic cancer and can induce EMT phenotype by directly degrading RKIP in pancreatic cancer PANC-1 cells.
CONCLUSIONS: We concluded that miR-181a induces EMT phenotype through its regulation of RKIP in pancreatic cancer. MicroRNA-18a may be a novel target in the treatment of pancreatic cancer in future. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; Raf-1 kinase inhibitor protein (RKIP); cancer stem cells (CSCs); epithelial to mesenchymal transition (EMT); microRNA-181a (miR-181a)

Year:  2020        PMID: 32395477      PMCID: PMC7210200          DOI: 10.21037/atm.2020.03.195

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Pancreatic cancer is a devastating invasive disease and is the fourth most common cause of deaths attributed to cancer in the USA (1).The high mortality of pancreatic cancer could, at least partly, be associated with metastasis. Epithelial to mesenchymal transition(EMT) plays a key role in metastasis of pancreatic cancer (2). Thus, understanding the molecular mechanism of EMT in pancreatic cancer is important in terms of improving pancreatic cancer prognosis. Previous research has found that Raf-1 kinase inhibitor protein (RKIP) is a suppressor of metastasis in human cancers (3). It is proposed that RKIP is a metastasis suppressor and a promising marker for predicting prognosis of pancreatic cancer. However, the function of RKIP in pancreatic cancer is still unclear (4). It is well-known that MicroRNAs (miRNAs/miR), as small non-coding RNAs with 19–25 nucleotides, play an essential role as post-transcriptional regulators to gene expression (5). Multiple genes regulated by miRNAs play crucial roles in migration, EMT, invasion, and tumor metastasis (6). This study aimed to explore the activity of RKIP in pancreatic cancer, so as to understand the molecular mechanism of metastasis of pancreatic cancer.

Methods

Sample collection of pancreatic cancer tissues

Cancer tissues from subjects with pancreatic cancer and adjacent normal tissues were collected tour hospital. All tissues were confirmed by pathologists.

Cell line PANC-1

Pancreatic ductal adenocarcinoma cell Line PANC-1was obtained from the Chinese Academy of Sciences (Shanghai, China) and cultured with Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (Invitrogen, San Diego, CA, USA) at 37 °C with 5% CO2.

Transfection experiments

RKIP expressing vectors were purchased from (Invitrogen, San Diego, CA, USA). Negative control miRNA (anti-miR) andpre-microRNA-181a (pre-miR-181a) were purchased from Ambion. The transfection process was conducted according to the manufacturers’ instructions. The incubation period lasted for 6 hours, before the medium was removed, and the cells were cultured with another medium for a further 48 hours.

Western blot analysis

Incubation with primary antibodies anti-RKIP, anti-N-Cadherin, anti-E-Cadherin, anti-SNAIL1, anti-Vimentin, anti-TGFB1, anti-Fibronectin, anti-CD44, anti-Tspan8 and anti-β-actin took place overnight at 4 °C. All primary antibodies were purchased from company (1:500; Abcam, Cambridge, MA, USA). IRDye TM-800 conjugated anti-rabbit secondary antibodies (Li-COR, Biosciences, Lincoln, NE, USA) were applied at room temperature for 2 hours. OdysseyTM Infrared Imaging System (Gene Company, Lincoln, NE, USA) was used to determine the specific protein.

Sphere growth and invasion assay

Cells (2.5×103/mL) were seeded for seven days on 0.5% agar precoated 6-well plates in serum-free RPMI1640/1 mM Na-pyruvate. Invasion assay was based on the protocol of the previous study (7) .

Quantitative polymerase chain reaction (qPCR) for microRNAs and RKIP

qPCR was performed as previously described (8). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a housekeeping gene for controlling RNA loading. The PCR primer sequences were: GAPDH: Forward-5'-CGGAGTCAACGG ATTTGGTCGTAT-3', Reverse-5'-AGCCTT CTCCATGGTGGTGAAGAC-3'. RKIP: Forward-5'-TATGCCGGTGGACCTCAG-3', Reverse-5'-CCTACTTCCCAGACAG-3'. Power SYBR Green PCR Master Mix (TAKARA Cat No. RR820W) was used in this study.

Immunofluorescence analyses

Immunofluorescence analyses were performed according to the manufacturer’s instructions. Briefly, anti-RKIP antibody was applied to stain transfected cells. The secondary antibodies were Alexa Fluor 488 goat anti-rabbit IgG antibody and Coverslips (Invitrogen). Use of a confocal laser-scanning microscope (Leica Microsystems, Bensheim, Germany) allowed us to make microscopic observations. The intensity of fluorescence was assessed in a small number of viewing areas with 300 cells for each coverslip, and ImageJ 1.37v software (http://rsb.info.nih.gov/ij/index.html) was used to conduct analysis.

Statistical analysis

Data analysis was conducted using SPSS20.0 software (SPSS Inc., II, Chicago, IL, USA), and the mean level of index between the two groups was determined by Student’s t-test. A P value <0.05 was deemed to be statistically significant.

Results

Pancreatic cancer sees lower RKIP expression

To assess the difference between the expression of RKIP mRNA in pancreatic cancer tissues in comparison with its expression in normal adjacent tissues, aqPCR was carried out for both sets of tissues. mRNA was separated from 56 pairs of cancerous tissues and adjacent normal tissues. Our results indicated that RKIP mRNA expression in the cancerous tissues were decreased in comparison with the adjacent normal tissues (). Western blotting was applied to identify protein isolated from the 6 pairs of cancer and adjacent normal tissues, and the results showed that the cancer tissues had lower RKIP expression ().
Figure 1

Expression of RKIP is downregulated in pancreatic cancer. RKIP, Raf-1 kinase inhibitor protein.

Expression of RKIP is downregulated in pancreatic cancer. RKIP, Raf-1 kinase inhibitor protein.

RKIP inhibits EMT in pancreatic cancer PANC-1 cells

To establish how RKIP operates in relation to pancreatic cancer, PANC-1 cells with RKIP-expressing plasmids were transfected. The results revealed that PANC-1cells transfected with RKIP-expressing plasmids showed slight changes in morphology in PANC-1 cells () and higher expression of RKIP protein ().
Figure 2

RKIP inhibits epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer PANC-1 cells. RKIP, Raf-1 kinase inhibitor protein. Scale bars, 50 μm.

RKIP inhibits epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer PANC-1 cells. RKIP, Raf-1 kinase inhibitor protein. Scale bars, 50 μm. To further verify that MET induced the changes of cell morphology. Expression levels of epithelial and mesenchymal markers were determined between PANC-1 cells that had been transfected with RKIP-expressing plasmids and the empty-vector cells. We found the E-Cadherin (epithelial marker) to be higher and N-Cadherin, Vimentin, SNAIL, TGFB1, and Fibronectin (mesenchymal markers) to be lower in PANC-1 cells that had received RKIP-expressing plasmids (). Our study also identified an RKIP-induced decrease in sphere formation in PANC-1 cells (). We also found that RKIP overexpression could suppress migration and invasion () in the cells.

miR-181a can degrade RKIP in PANC-1 cells

Our results established that an increase inmiR-181a was found in cells treated by pre-miR-181a (), as well as showing RKIP protein in the pre-miR-181a-transfected cells to be evidently suppressed ().
Figure 3

miR-181a can degrade RKIP in pancreatic cancer PANC-1 cells. RKIP, Raf-1 kinase inhibitor protein.

miR-181a can degrade RKIP in pancreatic cancer PANC-1 cells. RKIP, Raf-1 kinase inhibitor protein. Furthermore, immunofluorescence analysis was carried out in PANC-1 cells transfected with pre-miR-181a and control miR. In correspondence with the findings of the western blot, the results of immunofluorescence found RKIP protein to be demonstrably suppressed in the cells that had received pre-miR-181a (). RT-PCR and real-time PCR were then carried out to measure the expression of RKIP mRNA in PANC-1 cells transfected with pre-miR-181a or control miR. The RT-PCR results identified significant downregulation of RKIP mRNA () in the cells transfected with pre-miR-181a. Real-time PCR also came up with the same results ().

miR-181a can promote EMT

This study showed that expression of miR-181a was higher in cancerous tissues than in adjacent normal tissues (). Overexpression of miR-181a caused significant changes in PANC-1 cells morphology (EMT) (). The E-Cadherin (epithelial marker) was inhibited and N-Cadherin and SNAIL1 (mesenchymal markers) were induced by miR-181a in PANC-1 cells (). We also noted that miR-181a in PANC-1 cells increased sphere formation (). In addition, we found that miR-181a could suppress pancreatic cancer stem cell (CSC) markers (CD44 and Tspan8) in PCNA-1 cells (). To detect whether miR-181a could regulate migration and invasion, we performed invasion and migration assay. We found that miR-181a could indeed promote migration and invasion () in the cells.
Figure 4

miR-181a is upregulated in pancreatic cancer and it can promote EMT consistent with cancer stem cell phenotype in pancreatic cancer PANC-1 cells. EMT, epithelial-mesenchymal transition. Scale bars, 50 μm.

miR-181a is upregulated in pancreatic cancer and it can promote EMT consistent with cancer stem cell phenotype in pancreatic cancer PANC-1 cells. EMT, epithelial-mesenchymal transition. Scale bars, 50 μm.

Discussion

Raf-1 can lead to the development of tumor-related processes. Deregulated or constitutively active Raf-1 protein, for example, can contribute to changes in cells (9). Amplification and mutation of upstream regulators of Raf-1, including receptor tyrosine kinases (10) and Ras (11), often results in signaling deregulation in tumors via the Raf/MEK/ERK cascade. The activation of Raf-1 has been identified in cells which express oncogenic B-Raf proteins (12). More recently, it has been proposed that RKIP is a metastasis suppressor and could be a promising marker for predicting a better prognosis in pancreatic cancer (4). In line with earlier reports, we found that in pancreatic cancer there is a downregulation in RKIP expression. RKIP can inhibit EMT in line with CSC phenotype in PANC-1 cells. MEK/ERK signaling is avital part of a wide-ranging group of cellular functions including cell proliferation, differentiation and survival, and it can have a negative impact on the regulation of mouse embryonic stem cell (mESC) self-renewal by antagonizing STAT3 activity (13). We reason that RKIP might inhibit EMT by regulating MEK/ERK. Chemotherapy is a key therapy in the strategic treatment of pancreatic, but it does not succeed at killing all tumor cells, at least in part due to drug resistance of an intrinsic or acquired nature. Emerging evidence indicates that CSCs and EMT-type cells play an important and complicated role in anticancer drug resistance. Thus, we believe that RKIP had a significant effect on drug resistance in the treatment of pancreatic cancer. EMT cells can have features similar to CSCs, and CSCs exhibit mesenchymal phenotype under most circumstances. A correlation between aberrant miRNA expression, and the presence of CSCs and the acquisition of an EMT phenotype (14) has been identified. We found that miR-18a can promote EMT consistent with CSC phenotype by directly degrading RKIP in pancreatic cancer PANC-1 cells. PTEN is crucial for maintaining stem cells and a decrease can result in CSCs clones emerging and proliferating (15). The expression of PTEN can be suppressed by miR-181a in pancreatic cancer (16). Thus, we reasoned that miR-181a promotes CSC-like features, at least partly, by regulating RKIP and PTEN in pancreatic cancer. Moreover, miR-181a can promote migration by inhibiting MAP2K4 in pancreatic cancer. All the results indicate that miR-181 operates like an oncogene by controlling different tumor suppressive genes in pancreatic cancer. In conclusion, we established that miR-181a induces EMT phenotype by regulating RKIP in pancreatic cancer. MicroRNA-18a may be a novel target for treatment of pancreatic cancer in future. The article’s supplementary files as
  15 in total

Review 1.  Signal transduction and oncogenesis by ErbB/HER receptors.

Authors:  Mina D Marmor; Kochupurakkal Bose Skaria; Yosef Yarden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

2.  MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal.

Authors:  Jian Li; Guangwen Wang; Chengyan Wang; Yang Zhao; Hong Zhang; Zhijia Tan; Zhihua Song; Mingxiao Ding; Hongkui Deng
Journal:  Differentiation       Date:  2007-02-05       Impact factor: 3.880

3.  Mutational activation of c-raf-1 and definition of the minimal transforming sequence.

Authors:  G Heidecker; M Huleihel; J L Cleveland; W Kolch; T W Beck; P Lloyd; T Pawson; U R Rapp
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

Review 4.  Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Dejuan Kong; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Drug Resist Updat       Date:  2010-08-09       Impact factor: 18.500

Review 5.  Pancreatic cancer stem cells and EMT in drug resistance and metastasis.

Authors:  F H Sarkar; Y Li; Z Wang; D Kong
Journal:  Minerva Chir       Date:  2009-10       Impact factor: 1.000

6.  Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis.

Authors:  Yan Chen; Guo-Liang Ouyang; Hong Yi; Mao-Yu Li; Peng-Fei Zhang; Cui Li; Jian-Ling Li; Ying-Fu Liu; Zhu-Chu Chen; Zhi-Qiang Xiao
Journal:  J Proteome Res       Date:  2008-12       Impact factor: 4.466

7.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.

Authors:  Fanyin Meng; Roger Henson; Hania Wehbe-Janek; Kalpana Ghoshal; Samson T Jacob; Tushar Patel
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

8.  Reduced expression of Raf kinase inhibitor protein correlates with poor prognosis in pancreatic cancer.

Authors:  Shi-peng Song; Sheng-bin Zhang; Zhe-hai Li; Yong-sheng Zhou; Bing Li; Zhan-wei Bian; Qian-de Liao; Yang-de Zhang
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

9.  Depletion of MLKL inhibits invasion of radioresistant nasopharyngeal carcinoma cells by suppressing epithelial-mesenchymal transition.

Authors:  Yuanli Dong; Yun Sun; Yangle Huang; Xumeng Fang; Pian Sun; Bilikere Dwarakanath; Lin Kong; Jiade Jay Lu
Journal:  Ann Transl Med       Date:  2019-12

10.  MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells.

Authors:  Yong Lu; Michael Chopp; Xuguang Zheng; Mark Katakowski; Benjamin Buller; Feng Jiang
Journal:  Oncol Rep       Date:  2012-10-17       Impact factor: 3.906

View more
  4 in total

1.  MiR-573 suppresses cell proliferation, migration and invasion via regulation of E2F3 in pancreatic cancer.

Authors:  Zhou Pengcheng; Gao Peng; Fan Haowen; Lin Xida; Lu Yuhua; Wang Yao; Zhu Mingyan; Fan Xiangjun; Wang Zhiwei; Zhang Yewei; Wang Lei
Journal:  J Cancer       Date:  2021-03-19       Impact factor: 4.207

2.  MicroRNA‑181a promotes epithelial‑mesenchymal transition in esophageal squamous cell carcinoma via the TGF‑β/Smad pathway.

Authors:  Run Xu; Xue-Mei Zhou; Yu-Shan Li; Li Ren; Xin-Rong He
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

3.  Associations of miR-181a with Health-Related Quality of Life, Cognitive Functioning, and Clinical Data of Patients with Different Grade Glioma Tumors.

Authors:  Indre Valiulyte; Aiste Pranckeviciene; Adomas Bunevicius; Arimantas Tamasauskas; Hanna Svitina; Inessa Skrypkina; Paulina Vaitkiene
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

4.  MicroRNAs Deregulated in Intraductal Papillary Mucinous Neoplasm Converge on Actin Cytoskeleton-Related Pathways That Are Maintained in Pancreatic Ductal Adenocarcinoma.

Authors:  Elena Fernandez-Castañer; Maria Vila-Casadesus; Elena Vila-Navarro; Carolina Parra; Juan Jose Lozano; Antoni Castells; Meritxell Gironella
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.